Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KV4Z
|
|||
| Former ID |
DIB008978
|
|||
| Drug Name |
CI-949
|
|||
| Synonyms |
CI 949; UNII-EM1J51043X; EM1J51043X; L-Arginine, compd. with 5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide (1:1); OHOCQQJBKBVAFF-VWMHFEHESA-N; AC1L4M1L; AC1Q5G9U; 121530-58-3; SCHEMBL17041896; n5-(diaminomethylidene)-l-ornithine- 5-methoxy-1-phenyl-3-(propan-2-yloxy)-n-(2h-tetrazol-5-yl)-1h-indole-2-carboxamide(1:1); LS-21607; 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide L-arginate salt; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Discontinued in Phase 2 | [1] | |
| Company |
Dura Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H20N6O3
|
|||
| Canonical SMILES |
CC(C)OC1=C(N(C2=C1C=C(C=C2)OC)C3=CC=CC=C3)C(=O)NC4=NNN=N4
|
|||
| InChI |
1S/C20H20N6O3/c1-12(2)29-18-15-11-14(28-3)9-10-16(15)26(13-7-5-4-6-8-13)17(18)19(27)21-20-22-24-25-23-20/h4-12H,1-3H3,(H2,21,22,23,24,25,27)
|
|||
| InChIKey |
JPTSIWRGXIZEOO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 104961-19-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukotriene B4 receptor 1 (LTB4R) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Reactome | Leukotriene receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Spinal Cord Injury | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000104) | |||
| REF 2 | Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):902-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.